Home » Business, Health & Medicine, Pharmaceuticals & Biotech, Science, UK » Next Generation Cancer Diagnostics Market is Expected to Grow at the CAGR of 32.30% During 2015-2022: Brisk Insights
BriskInsights.com has announced the addition of “Global Next Generation Cancer Diagnostics Market Size, Share, Trends, Growth, Analysis And Forecast To 2022” Market Research Report to their Database.

According to a recently published report the Next Generation Cancer Diagnostics Market was estimated to grow around $2.95 billion in 2015 and is forecasted to reach around $20.93 billion growing at a CAGR of 32.30% during 2015-2022. The segmentation of next generation cancer diagnostics market is based on technology, function, cancer type, application and by geography. The report on next generation cancer diagnostics market forecast 2015-2022 (by technology, function, cancer type, application and geography) provides detailed summary as well as predictive analysis of the market.

Rising healthcare industry across the world is the key driver for the next generation cancer diagnostics market. The main reason behind the growth is the increasing number of cancer disease such as sex related cancers, blood-born cancer, lung cancer and others which directly help in boosting the demand for next generation cancer diagnostics in near future. There is an increased focus on high investments by various end user industries due to escalating number of hospitals and rising demand for miniaturized advanced technological devices which is expected to fuel the next generation cancer diagnostics market. Another major factor which drives this market is the technological up gradations which help in increasing the demand for this market. This next generation cancer diagnostics market also helps in reducing the long stay of a patient in the hospital and acts as a major driver for global next generation cancer diagnostics market. These are the major factors which help in fueling the global next generation cancer diagnostics market. Some of the challenges that are faced by the next generation cancer diagnostics market are the stringent regulatory guidelines and rising competition among market players which immensely affects the (NGCD) market globally. The major restraints of this market are the raising capital investment and dearth of experienced and skilled personnel that directly impacts and hinders the growth rate of next generation cancer diagnostics market.

Full report available global next generation cancer diagnostics market forecast 2015-2022 (by technology, function, cancer type, application and geography) report at http://www.briskinsights.com/report/next-generation-cancer-diagnostics-market

SCOPE OF THE REPORT

1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY TECHNOLOGY 2012 – 2022 ($ BILLION)
1.1. Lab-on-a-chip
1.2. DNA Microarrays
1.3. Multiplexed assays
1.4. RT-PCR & Multiplexing
1.5. Protein Microarrays
1.6. Cellular capture and identification
1.7. Next Generation Sequencing
1.8. Bench top Sequencers
1.9. Other Technologies

2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER TYPE 2012 – 2022 ($ BILLION)
2.1. Sex-related tumors
2.1.1. Cervical Cancer
2.1.2. Breast Cancer
2.1.3. Ovarian Cancer
2.1.4. Prostate Cancer
2.2. Blood-born cancers
2.2.1. Myeloma
2.2.2. Leukemia
2.2.3. Lymphoma
2.3. Lung Cancer
2.4. Solid tumors
2.5. Colorectal Cancer
2.6. Other Cancers

3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY FUNCTION 2012 – 2022 ($ BILLION)
3.1. Prognosis Diagnostics
3.2. Companion Diagnostics
3.3. Cancer Screening
3.4. Risk Analysis
3.5. Therapeutic Monitoring

4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY APPLICATION 2012 – 2022 ($ BILLION)
4.1. Proteomic Analysis
4.2. Epigenetic Analysis
4.3. Genetic Analysis
4.4. Biomarker Development
4.5. CTC Analysis

5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022($ BILLION)
5.1. NORTH AMERICA
5.2. EUROPE
5.3. ASIA PACIFIC
5.4. REST OF THE WORLD

6. COMPANY PROFILES
6.1. Abbott Laboratories
6.2. Agilent Technologies Inc
6.3. GE Healthcare
6.4. Genomic Health Inc.
6.5. Hologic Inc.
6.6. Illumina Inc.
6.7. Johnson & Johnson
6.8. Myriad Genetics Inc.
6.9. Novartis AG
6.10. Opko Health Inc.
6.11. Perkin Elmer Inc.
6.12. Philips Electronics NV
6.13. Qiagen
6.14. Roche Holding AG
6.15. Thermo Fisher Scientific Inc.

Full report available global next generation cancer diagnostics market forecast 2015-2022 (by technology, function, cancer type, application and geography) report at http://www.briskinsights.com/report/next-generation-cancer-diagnostics-market

About Us:

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to  aid businesses identify market opportunities optimize strategies.Our team of 200 analysts’ provides enterprises with strategic insights. Brisk Insights works to help enterprises grow through strategic insights and actionable solutions.Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.

Contact:

Name: Jennifer Smith

Desig: Manager Sales

E-mail: sales@briskinsights.com

Ph: +448081890034 (UK)

Web: Brisk Insights

Blog:  http://www.pdfdevices.com/global-next-generation-cancer-diagnostics-market-is-expected-to-reach-20-93-billion-by-2022-brisk-insights/

Media Contact
Company Name: Brisk Insights
Contact Person: Jennifer Smith, Manager – Sales
Email: sales@briskinsights.com
Phone: +448081890034 (UK)
Address:Office 1094 109 Vernon House Friar Lane
City: Nottingham
Country: United Kingdom
Website: http://www.briskinsights.com/report/next-generation-cancer-diagnostics-market

Comments are closed.